Suppr超能文献

血浆n-3脂肪酸对n-3脂肪酸补充剂的反应受载脂蛋白Eε4调节,但不受男性中常见的过氧化物酶体增殖物激活受体α(PPAR-α)L162V多态性调节。

Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men.

作者信息

Plourde Mélanie, Vohl Marie-Claude, Vandal Milène, Couture Patrick, Lemieux Simone, Cunnane Stephen C

机构信息

Research Centre on Aging, Université de Sherbrooke, Sherbrooke, Canada.

出版信息

Br J Nutr. 2009 Oct;102(8):1121-4. doi: 10.1017/S000711450938215X.

Abstract

The risk of Alzheimer's disease is increased for carriers of apoE4 (E4) or the PPAR-alpha L162V polymorphism (L162V), but it is decreased in fish and seafood consumers. The link between high fish intake and reduced risk of cognitive decline in the elderly appears not to hold in carriers of E4, possibly because better cognition is linked to EPA+DHA in the blood, but only in non-carriers of E4. As yet, no such studies exist in carriers of L162V. Our objective was to determine whether the plasma fatty acid response to a dietary supplement of EPA+DHA was altered in carriers of L162V and/or E4. This was an add-on project; in the original study, men were selected based on whether or not they were carriers of L162V (n 14 per group). E4 status was determined afterwards. All subjects received an EPA+DHA supplement for 6 weeks. L162V polymorphism did not interact with the supplement in a way to alter EPA and DHA incorporation into plasma lipids. However, when the groups were separated based on the presence of E4, baseline EPA and DHA in plasma TAG were 67 and 60 % higher, respectively, in E4 carriers. After the supplementation, there were significant gene x diet interactions in which only non-carriers had increased EPA and DHA in plasma NEFA and TAG, respectively.

摘要

载脂蛋白E4(E4)或过氧化物酶体增殖物激活受体α L162V多态性(L162V)的携带者患阿尔茨海默病的风险增加,但鱼类和海鲜消费者的患病风险降低。鱼类摄入量高与老年人认知能力下降风险降低之间的联系在E4携带者中似乎不成立,这可能是因为更好的认知能力与血液中的二十碳五烯酸(EPA)+二十二碳六烯酸(DHA)有关,但仅在非E4携带者中如此。迄今为止,尚未对L162V携带者进行此类研究。我们的目的是确定L162V和/或E4携带者对EPA+DHA膳食补充剂的血浆脂肪酸反应是否改变。这是一个附加项目;在原研究中,根据男性是否为L162V携带者进行分组(每组14人)。随后确定E4状态。所有受试者接受EPA+DHA补充剂6周。L162V多态性与补充剂之间没有相互作用,不会改变EPA和DHA掺入血浆脂质的情况。然而,当根据E4的存在情况对组进行划分时,E4携带者血浆甘油三酯(TAG)中的基线EPA和DHA分别高出67%和60%。补充后,存在显著基因×饮食相互作用,即只有非携带者血浆非酯化脂肪酸(NEFA)和TAG中的EPA和DHA分别增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验